What Analysts Recommend for Bluebird Bio Stock


Jul. 31 2018, Updated 3:25 p.m. ET

Analysts’ estimates and recommendations

As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.” 

Their consensus rating for Bluebird Bio is 2.14, which represents a “buy” for long-term growth investors and a moderate “buy” for value investors. The chart below shows analysts’ recommendations for Bluebird Bio stock over the last 12 months.

Article continues below advertisement

Analysts’ ratings

Bluebird Bio’s stock price has risen ~60.5% over the last 12 months but has fallen ~12.8% year-to-date. Analysts’ target price of $219.06 for the stock implies a ~41.1% upside to its July 30 price of $155.25.

Bluebird Bio’s valuation

Bluebird Bio’s forward EV[1.enterprise value]-to-sales multiple is 119.8x, while the industry average is ~33.6x. The VanEck Vectors Biotech ETF (BBH) invests 1.3% of its holdings in Bluebird Bio, 4.6% in BioMarin (BMRN), 5.6% in Celgene (CELG), and 5.4% in Allergan (AGN).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.